TL;DR
TB-500 is a synthetic 17–21 AA fragment of Thymosin Beta-4 that works systemically by sequestering G-actin via its WH2 domain, then releasing it explosively at injury signals — enabling whole-body mobilization of repair cells (fibroblasts, immune cells, endothelial progenitors) to damaged tissue. Where BPC-157 is the local architect, TB-500 is the logistics network. Uniquely reactivates the embryonic coronary development program in adult hearts post-MI. WADA banned; research-only.
Key Facts
| Status | Research-only · WADA banned (LC/HRMS detection: Ac-LKK, Ac-LKKTE in urine) |
| Class | Synthetic actin sequestrant / systemic regenerative / immunomodulator |
| Core mechanism | WH2 domain → G-actin sequestration → injury-triggered release → F-actin polymerization → system-wide cell migration |
| Half-life | Minutes in plasma; Ac-LKKTE metabolite maintains bioactivity after parent clears |
| Key benefit | Systemic repair cell delivery to avascular tissues; cardiac regeneration (EPDC mobilization); remyelination |
| Dosing | Loading 4–8 mg/week SubQ × 4–6 wks → maintenance 2–6 mg/month · 6-wk washout required |
| Main risk | Theoretical oncogenic risk (pro-angiogenic in undiagnosed malignancy); WADA ban |
| Evidence | Robust preclinical (cardiac, MS, wound healing); limited human off-label data |
Mechanism of Action
1. G-actin Sequestration (Core — WH2 Domain)
TB-500 binds G-actin via its WH2 domain (Wiskott-Aldrich syndrome homology 2), capping both barbed and pointed ends → prevents F-actin polymerization. The single salt bridge adjacent to the LKKT/V motif holds G-actin at physiological ionic strength. Injury signals alter local ionic concentration → bridge breaks → massive G-actin release → explosive F-actin polymerization at leading cell edge → cell propulsion toward wound.
Net effect: Removes the biomechanical barrier to cellular motility system-wide. Every immune cell, endothelial cell, myoblast, and stem cell becomes more mobile and responsive to chemotactic injury signals.
2. NF-κB / PINCH-1 / ILK Blockade
TB-500 physically binds PINCH-1/ILK intracellular signaling machinery → blocks IκB phosphorylation → NF-κB stays sequestered → suppresses TNF-α, IL-1β, IL-6, IL-8, MIP-1α, MIP-1β, MIP-2.
vs. GHK-Cu’s NF-κB suppression: GHK-Cu removes the oxidative trigger upstream; TB-500 blocks execution downstream — complementary anti-inflammatory axes.
3. M1→M2 Macrophage Polarization
- M1 (pro-inflammatory): drives chronic non-healing wounds
- M2 (pro-healing): secretes growth factors, drives remodeling
TB-500 drives rapid M1→M2 shift via SNAIL transcription factor upregulation + TLR4/NF-κB suppression → turns off acute inflammation, initiates tissue remodeling.
4. Ac-SDKP — Cardiac Angiogenesis Fragment
N-terminal Tβ4 derivative (cleaved by meprin and prolyl oligopeptidase) → potent coronary vasculogenesis + endothelial progenitor mobilization → reactivates embryonic coronary developmental program in adult hearts (Smart et al. 2007 Nature). First known molecule capable of generating new cardiomyocytes in vivo.
5. EGFR Remyelination
Upregulates EGFR signaling → NG2+ OPC proliferation → accelerated OPC maturation → CNPase+ cells + MBP upregulation → restored synaptic function, reduced axonal damage (EAE and cuprizone MS models).
Key Evidence
Cardiac (Most Quantified)
| Parameter | Healthy | MI + Vehicle | MI + Tβ4 |
|---|---|---|---|
| Ejection Fraction | 75.2% | 27.5% | 30.6% |
| Infarct size | — | 57.9% | 44.7% |
Standalone EF improvement ~5% at 28 days but tissue salvage is substantial. With GMT-expressing retroviruses (reprogramming fibroblasts to cardiomyocytes): functional cardiomyocyte percentage 51% vs. 35% vehicle.
Wound Healing
Tβ4-loaded hydrogel (2024–2025): at 14 days vs. controls: maximized CD31/α-SMA (neovascularization), maximized KI67 (proliferation), dramatically increased collagen I/III → lower collagen I:III ratio = fetal-pattern scarless healing. M1→M2 macrophage shift confirmed.
Wearable Biometric Effects
No direct wearable studies, but mechanism implies:
- HRV: NF-κB/M1→M2 shift → reduced systemic inflammation → improved parasympathetic tone over time
- Sleep: Anti-inflammatory effect + reduced nocturnal sympathetic tone → possible HRV/RHR improvement
- Recovery scores: Supports tissue repair speed — useful after injury or intense training cycles
Safety
| Risk | Detail |
|---|---|
| Oncogenic (theoretical) | Cannot mutate healthy cells. In undiagnosed malignancy: systemic pro-angiogenic + pro-migratory signaling could accelerate tumor vascularization/metastasis. Screen before use. Same caveat as BPC-157. |
| WADA | Banned in + out of competition. Detection via LC/HRMS urine metabolites. |
| Grey market | Peptide purity/identity risk — use verified sources. |
Key Stacks
| Stack | Partners | Rationale |
|---|---|---|
| Wolverine Stack | BPC-157 | BPC builds local vessel/structure; TB-500 recruits repair cells system-wide to that site |
| + GHK-Cu | Tissue architecture | TB-500 rapid structural work; GHK-Cu organizes collagen quality, provides copper/SOD antioxidant |
| + Retatrutide | Anti-sarcopenia | Retatrutide 28.7% weight loss → 25–45% lean loss; TB-500 counters lean tissue catabolism |
| + XW4475 | Hypertrophy safety | Rapid mTOR-driven hypertrophy outpaces connective tissue/blood supply; TB-500 keeps pace |
| + CJC-1295 Ipamorelin | GH amplification | IGF-1 from enhanced GH pulses → directed into tissue remodeling by TB-500 |
| + Epithalon | Telomere + repair | Epithalon extends replicative lifespan of cells doing the repair; TB-500 executes repair |
| + Glutathione | ROS buffering | TB-500-driven cell migration generates mitochondrial ROS; GSH prevents oxidative damage |
Dosing Summary
| Phase | Dose | Frequency | Duration |
|---|---|---|---|
| Loading | 4–8 mg/week total | 2–3× SubQ | 4–6 weeks |
| Maintenance | 2–6 mg/month total | 1–2× / month | 4–8 weeks |
| Washout | None | — | 6 weeks |
Oral route is completely non-viable. SubQ (systemic goals) or IM (deep muscle/ligament).
Links
- Peptides MOC
- BPC-157 — Wolverine Stack partner
- Tissue Repair — mechanism overlap
- GHK-Cu — tissue architecture synergy
- Retatrutide — anti-sarcopenia stack
- XW4475 — hypertrophy safety stack
- CJC-1295 Ipamorelin — GH amplification stack